Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIDIL vs GILENYA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.
Allergic rhinitis,Allergic conjunctivitis,Urticaria,Angioedema
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
0.5 mg orally once daily, with or without food
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
The terminal elimination half-life of fingolimod is approximately 6–9 days (mean 8.4 days). Due to the prolonged half-life, steady-state is achieved after 1–2 months of daily dosing, and lymphopenia may persist for up to 2 months after treatment cessation.
Hepatic via CYP450 isoenzymes (primarily CYP3A4 and CYP2D6); undergoes N-demethylation and N-oxidation.
Primarily metabolized by CYP4F2, and to a lesser extent by CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Extensive first-pass metabolism via reversible stereoselective phosphorylation to active metabolite fingolimod-phosphate; also undergoes oxidative metabolism. Elimination half-life is approximately 6-9 days.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Fingolimod is primarily eliminated via fecal excretion (81%) and to a lesser extent via renal excretion (<1% as unchanged drug). Biliary excretion accounts for a minor portion. The major metabolic pathway is via CYP4F2-mediated hydroxylation, followed by glucuronidation and elimination in feces.
Approximately 90% bound to plasma proteins, primarily albumin.
Fingolimod is approximately 99.7% bound to plasma proteins, primarily to albumin and lipoproteins (including α1-acid glycoprotein). The main active metabolite, fingolimod-phosphate, is also highly bound (>99%).
2.5-4.0 L/kg, indicating extensive tissue distribution.
The volume of distribution (Vd) is approximately 17 L/kg (range 7–30 L/kg), indicating extensive tissue distribution, especially into erythrocytes (about 20% of total drug in blood) and sequestration in central nervous system and lymphoid tissues.
Oral bioavailability is approximately 50-60% due to first-pass metabolism.
Oral bioavailability is approximately 93% (range 84–98%). Absorption is not significantly affected by food, but to reduce the risk of bradycardia and atrioventricular block, the first dose should be taken in the morning after a low-fat or fat-free meal.
GFR 10-50 m L/min: 2.5 mg every 6-8 hours; GFR <10 m L/min: 2.5 mg every 8-12 hours.
No dose adjustment required for mild to severe renal impairment including dialysis; monitor patients with severe renal impairment for bradycardia at treatment initiation
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh class A and B) but initiate with caution and monitor liver enzymes
Children 2-5 years: 1.25 mg orally every 4-6 hours (max 5 mg/day); Children 6-12 years: 1.25-2.5 mg every 4-6 hours (max 7.5 mg/day).
Approved for pediatric patients aged 10 years and older: for body weight ≤40 kg, 0.25 mg orally once daily; for body weight >40 kg, standard adult dose of 0.5 mg orally once daily
Initiate at 1.25 mg orally every 6-8 hours; maximum 5 mg per day due to increased risk of anticholinergic effects and renal impairment.
No specific dose adjustment recommended; use with caution due to potential for decreased renal function and increased sensitivity to bradycardia, monitor heart rate and blood pressure
None
Risk of bradyarrhythmia and atrioventricular block, requiring first-dose monitoring for at least 6 hours, including hourly pulse and blood pressure measurement, and ECG before and after first dose. Risk of infections, including fatal cryptococcal infections and other opportunistic infections. Risk of macular edema, especially in patients with uveitis or diabetes mellitus. Risk of posterior reversible encephalopathy syndrome (PRES). Risk of cutaneous malignancies (basal cell carcinoma, melanoma, Merkel cell carcinoma). Risk of fetal harm; advise females of reproductive potential of potential risk and need for effective contraception.
May cause drowsiness and impair mental alertness,Avoid alcohol and other CNS depressants,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Elderly patients are more susceptible to anticholinergic effects
Bradyarrhythmia: First-dose monitoring required; avoid in patients with sinoatrial block, sick sinus syndrome, second-degree or third-degree AV block unless pacemaker present.,Infections: Monitor for infections; consider suspending treatment if serious infection occurs. Vaccination against varicella zoster virus recommended before initiation.,Macular edema: Ophthalmologic evaluation before and 3-4 months after starting treatment; more frequent assessments in patients with diabetes or uveitis.,Respiratory effects: Dose-dependent decrease in forced expiratory volume and diffusion capacity; monitor pulmonary function if clinically indicated.,Elevated liver enzymes: Monitor liver enzymes before and during treatment; discontinue if significant liver injury occurs.,Fetal harm: Effective contraception required during and for 2 months after discontinuation.,Cutaneous malignancies: Baseline and routine dermatologic evaluations recommended.,Immune system effects: Avoid live attenuated vaccines during and for 2 months after treatment.,Posterior reversible encephalopathy syndrome (PRES): Evaluate rapidly if symptoms such as severe headache, altered mental status, visual disturbances, or seizures occur.,Increased blood pressure: Monitor blood pressure.,Reactivation of hepatitis B virus in carriers: Screen before initiation.,Tumor risk: Overall increased risk of malignancies, especially skin cancers and lymphomas.
Hypersensitivity to any component,Concurrent use with monoamine oxidase inhibitors
Hypersensitivity to fingolimod or any excipient,Recent myocardial infarction (within last 6 months),Unstable angina,Stroke or transient ischemic attack (within last 6 months),History of second-degree Mobitz type II or third-degree AV block, sick sinus syndrome, or sinoatrial block unless patient has an implanted pacemaker,Baseline QTc interval ≥500 msec,Treatment with Class Ia or Class III antiarrhythmics,Severe untreated sleep apnea,Concomitant use of pimozide
No specific food interactions, but taking with food may reduce GI side effects. Alcohol should be strictly avoided due to additive CNS depression. Grapefruit juice is not documented to interact.
No significant food interactions reported; take with or without food. Avoid grapefruit juice? No known interaction.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergic effects may cause neonatal tachycardia, irritability, and withdrawal symptoms if used near term.
FDA Pregnancy Category C. First trimester: potential for fetal harm based on animal studies (increased incidence of fetal malformations, including ventricular septal defects, at doses similar to human exposure). Second and third trimesters: limited human data; animal studies show reduced fetal weight and increased fetal mortality. Risk cannot be excluded; use only if benefit outweighs risk.
Excretion into breast milk likely but negligible amounts; no adverse effects reported in infants. M/P ratio not established. Considered compatible with breastfeeding; monitor for sedation or irritability in neonate.
Not recommended during breastfeeding. Fingolimod is excreted in animal milk; unknown if excreted in human milk. M/P ratio not established. Potential for serious adverse reactions in nursing infants, including bradycardia, infections, and immunosuppression.
No specific dose adjustments required in pregnancy; however, use lowest effective dose due to potential anticholinergic effects. Pharmacokinetics may be altered (increased volume of distribution), but no dose adjustment recommended.
No established dose adjustment in pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, decreased protein binding) may reduce exposure; consider therapeutic drug monitoring if available. Discontinue if pregnancy occurs unless benefit clearly outweighs risk.
ACTIDIL (triprolidine) is a first-generation antihistamine with sedative properties. Use cautiously in elderly due to risk of confusion, urinary retention, and falls. Avoid in patients with narrow-angle glaucoma, BPH, or asthma. Administer with food if GI upset occurs. Onset of action is 30-60 minutes; duration 4-6 hours.
GILENYA (fingolimod) requires first-dose monitoring for 6 hours due to risk of bradyarrhythmia; obtain baseline ECG, CBC, LFTs, and ophthalmologic exam. Avoid in patients with recent MI, unstable angina, stroke, or certain arrhythmias. Monitor for infections, especially cryptococcal meningitis and PML. Rebound disease activity may occur upon discontinuation. Lymphopenia is expected; monitor lymphocyte counts regularly.
Do not drive or operate heavy machinery until you know how this medication affects you; it can cause drowsiness.,Avoid alcohol and other CNS depressants, as they may increase sedation.,Take exactly as prescribed; do not exceed recommended dose.,If you miss a dose, skip it; do not double the next dose.,Notify your doctor if you experience blurred vision, difficulty urinating, or severe drowsiness.,Do not use for prolonged periods without medical advice.
Take exactly as prescribed; do not skip doses without consulting your doctor.,You will need a 6-hour observation period after the first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) or visual changes immediately.,Do not receive live vaccines while taking this medication.,Use effective contraception during treatment and for 2 months after stopping, as it may harm a fetus.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIDIL vs GILENYA, answered by our medical review team.
ACTIDIL is a Antihistamine that works by H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.. GILENYA is a Sphingosine 1-Phosphate Receptor Modulator that works by Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIDIL and GILENYA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIDIL is: 2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.. The standard adult dose of GILENYA is: 0.5 mg orally once daily, with or without food. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIDIL and GILENYA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIDIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergi. GILENYA is classified as Category C. FDA Pregnancy Category C. First trimester: potential for fetal harm based on animal studies (increased incidence of fetal malformations, including ventricular septal defects, at do. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.